Skin cancer, particularly basal cell carcinoma (BCC), affects millions annually in the U.S., with current treatments primarily surgical, highlighting a significant unmet need for non-invasive options. Medicus Pharma Ltd., through its subsidiary SkinJect Inc., is addressing this gap with a patented dissolvable microneedle patch that delivers chemotherapy directly to tumor cells, offering a promising alternative to traditional surgery.
The microneedle patch, designed for painless drug delivery, has shown encouraging results in early trials, with over 60% of participants in a Phase 2 study achieving complete clinical clearance. The treatment's potential for significant cost savings and immediate administration post-diagnosis positions it as a groundbreaking development in skin cancer care.
Medicus's expansion into veterinary medicine, targeting squamous cell carcinoma in horses, further underscores the versatility and broad applicability of its technology. With the skin cancer treatment market projected to grow, Medicus's innovative approach could capture a substantial share, benefiting patients and investors alike.
The company's strategic acquisitions and funding initiatives, including a recent $7 million public offering, reflect strong investor confidence and a commitment to advancing its clinical programs. As Medicus progresses towards FDA approval, its non-invasive treatment could redefine standards of care for BCC and beyond.
